Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 5th International Conference of Orthopedic Surgeons and Rheumatology Alicante, Spain.

Submit your Abstract
or e-mail to

Day 1 :

Keynote Forum

Joseph Purita

Director Institute of Regenerative and Molecular Orthopedics
U.S.A.

Keynote: Cutting edge concepts in the use of Stem Cell and PRP Injections in an office setting
OMICS International Rheumatology2016 International Conference Keynote Speaker Joseph Purita  photo
Biography:

Dr. Purita is director of Institute of Regenerative and Molecular Orthopedics (www.stemcellorthopedic.com) in Boca Raton, Florida. The Institute specializes in the use of Stem Cells and Platelet Rich Plasma injections. Dr. Purita is a pioneer in the use of Stem Cells and Platelet Rich Plasma. The Institute has treated some of the most prominent professional athletes from all major sports in both the U.S.A. and abroad. He received a B.S. and MD degree from Georgetown Univ. Dr. Purita is board certified in Orthopedics by ABOS. He is a Fellow American College of Surgeons, Fellow American Academy Orthopedic Surgeons, and a Fellow American Academy of Pain Management. He is also certified in Age Management Medicine. He has lectured and taught extensively throughout the world on the use of Stem Cells and Platelet Rich Plasma. He has been instrumental in helping other countries in the world establish guidelines for the use of Stem Cells in their countries. He has been invited to lecture on these techniques throughout the world as a visiting professor.

Abstract:

The presentation concerns PRP and Stem Cell (both bone marrow and adipose) injections for musculoskeletal conditions in an office setting. Indications are given as to which type of cell and technique to use to accomplish repair. Stem cells, both bone marrow derived (BMAC) and adipose, are used for the more difficult problems. PRP injections are utilized for the less severe problems. Indications are given when to use Stem Cells verses PRP and when to use both. The newest concepts in stem cell science are presented. These concepts include the clinical use of MUSE cells, exosomes and Blastomere like stem cells. Basic science of both PRP and stem cells are discussed. This presentation defines what constitutes an effective PRP preparation. Myths concerning stem cells are dispelled. One myth is that mesenchymal stem cells are the most important stem cell. This was the initial interpretation of Dr. Arnold Caplan the father of mesenchymal stem cell science. Dr. Caplan now feels that MSCs have an immunomodulation capacity which may have a more profound and immediate effect on joint chemistry and biology. We now learn in the talk that the hematopoietic stem cells are the drivers of tissue regeneration. Also discussed are adjuncts used which enhance the results. These therapies include supplements, LED therapy, lasers, electrical stimulation and cytokine therapy. The scientific rationale is presented for each of these entities as to how they have a direct on stem cells.

Keynote Forum

Jozef Rovenský

National Institute of Rheumatic Disease, Piestany
Slovakia

Keynote: Alkaptonuria and Ochronosis

Time : 09:25 - 09:55

OMICS International Rheumatology2016 International Conference Keynote Speaker Jozef Rovenský photo
Biography:

Prof. MD. Jozef Rovno, MD., FRCP since 1990, is director of the National Institute of Rheumatic Diseases in. It is extremely active publication, published in domestic and foreign journals with high citation index and has more than 120 citations in domestic and foreign magazines. He holds the Gold Medal revaluation of the Slovak Medical Association for his active work in the medical field. It is the President or no lenom in many organizations and a member of the editorial boards of journals: Newsletter LPRE SR Rheumatologia, medical monitor, Osteologický bulletin Scripta Medica 2000 Clinical Experimental Rheumatology.

Abstract:

Alkaptonuria is a rare inherited genetic disorder of phenylalanine and tyrosine metabolism. This is an autosomal recessive condition that is due to a defect in the enzyme homogentisate 1,2-dioxygenase, which participates in the degradation of tyrosine. As a result, homogentisic acid and its oxide, accumulate in the blood and are excreted in urine in large amounts. The polymer of homogentisc acid called alkapton, impregnates bradotrophic tissues. rnThe first signs of deposition of the ochronotic pigment can be detected accidentally during professional examination of the anterior segment of the eye. The ochronotic pigmentation of the ocular structures is present in approximately 70 % of patients. In addition to the sclera, lumps of the ochronotic pigment can be found in the conjunctiva and cornea. Since similar pigmentation of the cornea is not present in other medical conditions, this finding is regarded as pathognomic for alkaptonuric ochronosis. The diagnosis of alkaptonuria is based on the characteristic findings in urine. Alkaptonuria patients do not seek medical help due to difficulties with vision – they are without subjective complications. In parallel with the ocular manifestations, ochronotic changes can be found in the hearing organ. Color changes of the auricle are visible in the 10th to 15th year of life. Also typical for alkaptonuric ochronosis are changes in the skin, mainly brownish or bluish pigmentation of the skin under the arm, in the face, neck and hands, and rarely on the nails. Given their visibility they may be relevant for the early diagnosis alkaptonuric ochronosis. Ochronotic pigment is deposited also on the internal organs. In the field of cardiovascular organs it is the myocardium and blood vessels. From a clinical point of view, the most serious process takes place in the joints and is called ochronotic arthropathy. Therapy of alkaptonuria with Nitisinone is underway.